<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01238159</url>
  </required_header>
  <id_info>
    <org_study_id>2010-06-019</org_study_id>
    <nct_id>NCT01238159</nct_id>
  </id_info>
  <brief_title>Concomitant Chemo-radiotherapy Followed by MIDLE Chemotherapy in Stage I/II Extranodal NK/T-cell Lymphoma</brief_title>
  <official_title>Open-labeled, Multicenter Phase II Study of Concomitant Chemo-radiotherapy Followed by MIDLE (Methotrexate, Ifosfamide, Dexamethasone, L-asparaginase, Etoposide) Chemotherapy in Stage I/II Extranodal NK/T-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonnam National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of concomitant chemoradiation followed
      by MIDLE chemotherapy for stage I/II extranodal NK/T cell lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Concomitant chemo-radiotherapy:

      Radiation 36-44 Gy/18-22 fractions (2 Gy/fraction) Weekly Cisplatin 30mg/m2 + N/S 100ml MIV
      over 30min Tri-weekly L-asparaginase 4000 IU IV (D1, 3, 5)

      Rest period: 3 weeks

      MIDLE chemotherapy: Repeated every 28 days for 2 cycles D1 Methotrexate 3g/m2 + D5W 500ml MIV
      over 6 hours D2-D3 Etoposide 100mg/m2 + D5W 500ml MIV over 90mins D2-D3 Ifosfamide 1000mg/m2
      + D5W 100ml MIV over 1hr D2-D3 Mesna 300mg/m2 + D5W 100ml MIV over 15mins (-15min, 4hrs and
      8hrs after ifosfamide, total 3 doses) D1-D4 Dexamethasone 40mg/d PO or IV D4, 6, 8, 14, 10
      L-asparaginase 6000IU/m2 + D5W 500ml MIV over 2hours
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response</measure>
    <time_frame>Within 4 weeks after the completion of planned treatment</time_frame>
    <description>The response criteria was based on the International Working Group Report (1999).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Overall response rate includes complete and partial response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Overall survival is defined as the time interval between the date of diagnosis and the date of death with any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Progression-free survival is defined as the time interval between the the date of diagnosis and the date of death with any cause or disease progression/relapse.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type</condition>
  <arm_group>
    <arm_group_label>CCRT+MIDLE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who are planned to be treated with CCRT plus MIDLE chemotherapy. CCRT means concurrent chemoradiation, and MIDLE represent systemic chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>CCRT+MIDLE chemotherapy</intervention_name>
    <description>Patients are planned to be treated with CCRT plus MIDLE chemotherapy</description>
    <arm_group_label>CCRT+MIDLE</arm_group_label>
    <other_name>Chemoradiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients were required to have a biopsy-proven diagnosis of nasal ENKTL

          -  at least 18 years old

          -  Ann Arbor stage IE or IIE

          -  measurable disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 life expectancy
             greater than 12 weeks

          -  adequate hematologic (hemoglobin &gt; 9.0 g/dL, absolute neutrophil count &gt; 1,500/uL and
             platelets &gt; 100,000/uL)

          -  renal (serum creatinine &lt; 1.5 mg/dL, creatinine clearance &gt; 50 mL/min)

          -  hepatic (total bilirubin &lt; 2 times of upper limit of normal and aspartate transferase
             &lt; 3 times of upper limit of normal) function

          -  Diagnosis of ENKTL is based on the presence of histological features and
             immunophenotypes compatible with ENKTL (e.g., cytoplasmic CD3+, CD20-, CD56+,

          -  positive for cytotoxic molecules

          -  positive for EBV by in situ hybridization).

          -  Informed consent

        Exclusion Criteria:

          -  prior or concomitant malignant tumors

          -  any coexisting medical problems of sufficient severity to prevent full compliance with
             the study protocol.

          -  ENKTL with non-nasal sites such as skin or gastrointestinal tract was excluded even if
             it is localized.

          -  Other subtypes of non-Hodgkin lymphoma (NHL), including myeloid/NK cell precursor
             acute leukemia, blastic NK cell lymphoma/precursor NK cell lymphoblastic leukemia,
             aggressive NK cell leukemia, and peripheral T cell lymphoma, unspecified, were
             excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Won Seog Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2010</study_first_submitted>
  <study_first_submitted_qc>November 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2010</study_first_posted>
  <last_update_submitted>March 1, 2015</last_update_submitted>
  <last_update_submitted_qc>March 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Kim, Seok Jin</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Natural killer cell</keyword>
  <keyword>T cell</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Radiation</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

